Patents Assigned to Central Adelaide Local Health Network Incorporated
  • Publication number: 20230193389
    Abstract: The present invention related to the proline rich transmembrane protein 2 (PRRT2) gene, and the identification of mutations and variations in PRRT2 that give rise to seizure and movement disorders. Accordingly, the present invention provides methods for the diagnosis or prognosis of such disorders by identifying alterations in the PRRT2 gene. Identification of alterations in the PRRT2 gene also enables the identification of subjects with an increased likelihood of having an offspring predisposed to such disorders. The present invention also provides an isolated nucleic acid molecule comprising an alteration in the PRRT2 gene, wherein said alteration produces a seizure and/or movement disorder phenotype. Also provided is an isolated PRRT2 polypeptide that comprises an alteration which produces a seizure and/or movement disorder phenotype.
    Type: Application
    Filed: October 17, 2022
    Publication date: June 22, 2023
    Applicants: ITEK VENTURES PTY LTD, The University of Melbourne, Central Adelaide Local Health Network Incorporated
    Inventors: Sarah Elizabeth Heron, Leanne Michelle Dibbens, Samuel Frank Berkovic, Ingrid Eileen Scheffer, John Charles Mulley
  • Patent number: 11473143
    Abstract: The present invention relates to the proline rich transmembrane protein 2 (PRRT2) gene, and the identification of mutations and variations in PRRT2 that give rise to seizure and movement disorders. Accordingly, the present invention provides methods for the diagnosis or prognosis of such disorders by identifying alterations in the PRRT2 gene. Identification of alterations in the PRRT2 gene also enables the identification of subjects with an increased likelihood of having an offspring predisposed to such disorders. The present invention also provides an isolated nucleic acid molecule comprising an alteration in the PRRT2 gene, wherein said alteration produces a seizure and/or movement disorder phenotype. Also provided is an isolated PRRT2 polypeptide that comprises an alteration which produces a seizure and/or movement disorder phenotype.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: October 18, 2022
    Assignees: The University of Melbourne, Central Adelaide Local Health Network Incorporated, Itek Ventures PTY Ltd (University of South Australia)
    Inventors: Sarah Elizabeth Heron, Leanne Michelle Dibbens, Samuel Frank Berkovic, Ingrid Eileen Scheffer, John Charles Mulley
  • Patent number: 10538811
    Abstract: An isolated nucleic acid molecule comprising the nucleotide sequence set forth in SEQ ID NO: 1.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: January 21, 2020
    Assignee: Central Adelaide Local Health Network Incorporated
    Inventors: Jozef Gecz, Petter Stromme
  • Publication number: 20180030536
    Abstract: The present invention relates to the proline rich transmembrane protein 2 (PRRT2) gene, and the identification of mutations and variations in PRRT2 that give rise to seizure and movement disorders. Accordingly, the present invention provides methods for the diagnosis or prognosis of such disorders by identifying alterations in the PRRT2 gene. Identification of alterations in the PRRT2 gene also enables the identification of subjects with an increased likelihood of having an offspring predisposed to such disorders. The present invention also provides an isolated nucleic acid molecule comprising an alteration in the PRRT2 gene, wherein said alteration produces a seizure and/or movement disorder phenotype. Also provided is an isolated PRRT2 polypeptide that comprises an alteration which produces a seizure and/or movement disorder phenotype.
    Type: Application
    Filed: July 28, 2017
    Publication date: February 1, 2018
    Applicants: ITEK VENTURES PTY LTD, The University of Melbourne, Central Adelaide Local Health Network Incorporated
    Inventors: Sarah Elizabeth HERON, Leanne Michelle Dibbens, Samuel Frank Berkovic, Ingrid Elleen Scheffer, John Charles Mulley
  • Patent number: 9828351
    Abstract: The present disclosure relates generally, but not exclusively, to compounds and their use as enzyme interacting agents, in particular, agents which interact with one or more enzymes in the sphingolipid biosynthesis pathway. The disclosure further relates to the use of such compounds as research tools, use in therapy, to compositions and agents comprising said compounds, and to methods of treatment using said compounds.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: November 28, 2017
    Assignees: MONASH UNIVERSITY, UNIVERSITY OF SOUTH AUSTRALIA, CENTRAL ADELAIDE LOCAL HEALTH NETWORK INCORPORATED
    Inventors: Bernard Luke Flynn, Luigi Aurelio, Carmen Vittoria Scullino, Bing Hui Wang, Stuart Maxwell Pitson, Melissa Rose Pitman
  • Patent number: 9752193
    Abstract: The present invention relates to the proline rich transmembrane protein 2 (PRRT2) gene, and the identification of mutations and variations in PRRT2 that give rise to seizure and movement disorders. Accordingly, the present invention provides methods for the diagnosis or prognosis of such disorders by identifying alterations in the PRRT2 gene. Identification of alterations in the PRRT2 gene also enables the identification of subjects with an increased likelihood of having an offspring predisposed to such disorders. The present invention also provides an isolated nucleic acid molecule comprising an alteration in the PRRT2 gene, wherein said alteration produces a seizure and/or movement disorder phenotype. Also provided is an isolated PRRT2 polypeptide that comprises an alteration which produces a seizure and/or movement disorder phenotype.
    Type: Grant
    Filed: October 29, 2012
    Date of Patent: September 5, 2017
    Assignees: The University of Melbourne, Central Adelaide Local Health Network Incorporated, Itek Ventures Pty Ltd (University of South Australia)
    Inventors: Sarah Elizabeth Heron, Leanne Michelle Dibbens, Samuel Frank Berkovic, Ingrid Eileen Scheffer, John Charles Mulley
  • Patent number: 9631234
    Abstract: An isolated nucleic acid molecule comprising the nucleotide sequence set forth in SEQ ID NO: 1.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: April 25, 2017
    Assignee: Central Adelaide Local Health Network Incorporated
    Inventors: Jozef Gecz, Petter Stromme
  • Publication number: 20130340101
    Abstract: An isolated nucleic acid molecule comprising the nucleotide sequence set forth in SEQ ID NO: 1.
    Type: Application
    Filed: November 30, 2012
    Publication date: December 19, 2013
    Applicant: CENTRAL ADELAIDE LOCAL HEALTH NETWORK INCORPORATED
    Inventor: Central Adelaide Local Health Network Incorporate
  • Patent number: 8323885
    Abstract: An isolated nucleic acid molecule comprising the nucleotide sequence set forth in SEQ ID NO: 1.
    Type: Grant
    Filed: November 26, 2002
    Date of Patent: December 4, 2012
    Assignee: Central Adelaide Local Health Network Incorporated
    Inventors: Jozef Gecz, Petter Stromme